| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DKFZp564G072; FLJ95923; Frizzled-1; Fz-1; FZD1; FzE1; hFz1; Wnt receptor |
| Entrez GeneID | 8321; |
| WB Predicted band size | 71kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to residues near the N terminal of human Frizzled family receptor 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FZD1抗体的3篇示例参考文献(注：以下内容为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Monoclonal Antibody Targeting FZD1 Suppresses Wnt Signaling in Colorectal Cancer Models*
**作者**：Zhang, Y. et al.
**摘要**：研究开发了一种针对FZD1胞外结构域的单克隆抗体，证实其可特异性抑制WNT/β-catenin通路，并在结直肠癌小鼠模型中显著减少肿瘤生长，提示其作为靶向治疗的潜力。
---
2. **文献名称**：*FZD1 Expression in Triple-Negative Breast Cancer: Validation of a Novel Antibody for Prognostic Assessment*
**作者**：Patel, R. & Kumar, S.
**摘要**：通过新型兔源多克隆抗体检测FZD1在乳腺癌组织中的表达，发现FZD1高表达与患者不良预后相关，为TNBC的分子分型提供了工具。
---
3. **文献名称**：*FZD1 Antibody-Based Blockade Attenuates Cardiac Fibrosis via Modulating Wnt Pathways*
**作者**：Gomez, L. et al.
**摘要**：利用FZD1中和抗体阻断Wnt信号，在小鼠心肌纤维化模型中观察到胶原沉积减少和心脏功能改善，揭示了FZD1在纤维化中的调控机制。
---
建议通过 **PubMed** 或 **Google Scholar** 检索关键词“FZD1 antibody”、“FZD1 Wnt signaling”获取最新研究。真实文献可能涉及抗体开发、疾病机制或治疗应用等领域。
The Frizzled class receptor 1 (FZD1) antibody is a research tool designed to detect and study FZD1. a member of the Frizzled family of G protein-coupled receptors. FZD1 plays a critical role in the Wnt signaling pathway, which regulates embryonic development, cell polarity, proliferation, and tissue homeostasis. As a seven-pass transmembrane receptor, FZD1 binds Wnt ligands via its extracellular cysteine-rich domain (CRD), initiating downstream signaling cascades such as the canonical β-catenin-dependent pathway and non-canonical β-catenin-independent pathways (e.g., planar cell polarity or calcium signaling). Dysregulation of FZD1-mediated signaling has been implicated in cancers, metabolic disorders, and developmental abnormalities.
FZD1 antibodies are widely used in biomedical research to investigate receptor expression, localization, and function. They enable techniques like Western blotting, immunohistochemistry, and flow cytometry to analyze FZD1 levels in normal versus diseased tissues. Such studies help elucidate FZD1's role in tumor progression, stem cell maintenance, and tissue regeneration. Additionally, FZD1 antibodies support drug discovery efforts targeting Wnt signaling, particularly in cancers where pathway hyperactivation is common. Commercial FZD1 antibodies are typically validated for specificity against the receptor’s CRD or intracellular domains, though variability in performance across experimental models requires careful validation. Ongoing research continues to explore FZD1 as a therapeutic target and biomarker.
×
